HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
April 05, 2024 10:00 ET
|
HiberCell, Inc.
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
March 27, 2024 08:00 ET
|
Vector Pharma FZCO; Oncopeptides AB
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies
January 30, 2024 02:30 ET
|
Qubit Pharmaceuticals
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer...
PR : Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery
January 08, 2024 02:00 ET
|
ULYSSE COMMUNICATION
Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery Paris, France, 8 January, 2023 – Iktos, a company specialized in Artificial...
Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology
December 05, 2023 12:26 ET
|
Syapse
Research collaboration between Syapse and the FDA Oncology Center of Excellence extended to assess fit-for-purpose RWD and explore the potential of RWE.
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
November 08, 2023 07:30 ET
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
September 06, 2023 07:30 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
April 27, 2023 07:40 ET
|
HCW Biologics, Inc
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the...
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
November 08, 2022 07:00 ET
|
HCW Biologics, Inc
Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218 TGF-β trap HCW9218 is one of the lead...
Axtria To Present New Ways To Leverage Advanced Analytics To Forecast and Understand Oncology Market Dynamics @ PMSA Fall Symposium
October 27, 2022 07:00 ET
|
Axtria Inc.
Las Vegas, Nevada, Oct. 27, 2022 (GLOBE NEWSWIRE) -- New approaches for using data analytics for predicting the future growth of both the overall oncology market as well as the adoption and...